Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue

Overview

We will conduct a phase 4, multicenter, open-label trial at 7 academic centers in Taiwan. Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir disoproxil fumarate [TDF]) for at least 2 years, and fulfil the following nucleos(t)ide analogs discontinuation criteria. After nucleos(t)ide analogs discontinuation, patients had a clinical relapse and retreatment regimen switches to TAF. The protocol will be approved by Institutional Review Board (IRB) or Research ethic committee (REC) of each site and will be conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. Each patient provides written informed consent before enrollment.

Full Title of Study: “The Clinical Efficacy of Tenofovir Alafenamide-switching Therapy in Patients With Chronic Hepatitis B Experiencing Clinical Flare-up After Discontinuation of Nucleos[t]Ide Analogues Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2022

Detailed Description

Tenofovir alafenamide (TAF) is a new generation of oral antiviral drugs with similar antiviral activities to tenofovir disoproxil fumarate (TDF) and reduces the adverse effects of nephrotoxicity and bone mineral density reduction. This drug has already been reimbursed by National Health Insurance, and can be used for the treatment of patients with chronic hepatitis B. This is a single-arm prospective clinical trial to enroll patients who discontinued entecavir (ETV) and tenofovir disoproxil fumarate (TDF) and experienced a clinical hepatitis flare up. They can be retreated with TAF for 48 weeks without postponing a 3-month observation period for alanine aminotransferase (ALT) level. The virological control, ALT level recovery, and changes in liver fibrosis, hepatitis B surface antigen, hepatitis B core-associated antigen, and renal function will be observed during retreatment. In addition, a group of patients with the same characteristics who received retreatment with entecavir or TDF will be collected as a control group for comparison. We believe this study can help us understand the clinical benefits of switching to TAF for retreatment after hepatitis flare in patients to discontinue oral antiviral agents.

Interventions

  • Drug: Vemlidy
    • 25mg Tenofovir Alafenamide

Arms, Groups and Cohorts

  • Experimental: Switching therapy cohort
    • single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
  • No Intervention: Historical continuing therapy cohort
    • By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)

Clinical Trial Outcome Measures

Primary Measures

  • Rate of virological remission (HBV DNA <20 IU/mL)
    • Time Frame: 48 weeks
    • We will calculate the rate of virological remission (HBV DNA <20 IU/mL) after retreatment

Secondary Measures

  • Rate of ALT normalization (ALT < 40 U/L) after retreatment
    • Time Frame: 48 weeks
    • We will calculate the rate of ALT normalization (ALT < 40 U/L) after retreatment
  • Rate of HBsAg change after retreatment compared with baseline
    • Time Frame: 48 weeks
    • We will investigate the rate of HBsAg change after retreatment compared with the baseline HBsAg
  • Rate of HBcrAg change after retreatment compared with baseline
    • Time Frame: 48 weeks
    • We will investigate the rate of hepatitis B core-related antigen (HBcrAg) change after retreatment compared with baseline HBcrAg
  • Rate of M2BPGi level change after retreatment compared with baseline
    • Time Frame: 48 weeks
    • We will investigate the rate of Mac-2 binding protein glycosylation isomer (M2BPGi) level change after retreatment compared with baseline M2BPGi level

Participating in This Clinical Trial

Inclusion Criteria A. Switching therapy cohort 1. Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least 2 years, and fulfil the following NUCs discontinuation criteria (1)HBeAg-positive patients achieving HBeAg seroclearance, and received at least 1-year consolidation therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1 year (on 3 occasions, 6 months apart) 2. After NUC discontinuation, patients had a clinical relapse (HBV DNA > 2000 IU/mL, and ALT > 2x ULN) 3. The retreatment regimen switches to TAF (within 3 months of clinical relapse) B. Historical continuing therapy cohort 1. Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least 2 years, and fulfil the following NUCs discontinuation criteria (1) HBeAg-positive patients achieving HBeAg seroclearance, and received at least 1-year consolidation therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1 year(on 3 occasions, 6 months apart) 2. After NUC discontinuation, patients had a clinical relapse (HBV DNA > 2000 IU/mL, and ALT > 2x ULN) 3. The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse) Exclusion Criteria 1. Patients who do not fulfill the discontinuation criteria 2. Patients who have HCV, HDV or HIV co-infection 3. Patients who discontinue lamivudine, adefovir, or telbivudine therapy 4. Patients with liver cirrhosis by ultrasonography and clinical diagnosis

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Taiwan University Hospital
  • Collaborator
    • National Taiwan University Hospital, Yun-Lin Branch
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tung-Hung Su, MD, PhD, Principal Investigator, National Taiwan University Hospital
  • Overall Contact(s)
    • Tung-Hung Su, MD, PhD, 886972651694, tunghungsu@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.